At Eli Lilly and Company, I reviewed pharmaceutical promotional and non-promotional materials for US marketing operations, applying FDA-aligned requirements across 20 drugs and six therapeutic areas. I also served as Quality Insights Report Lead for the Neuroscience Business Unit, evaluating materials to identify compliance gaps and labeling accuracy issues.
I supported six product launches, including Omvoh, Inluriyo, BAQSIMI, and Rezvoglar, by providing editorial and regulatory compliance support. I also managed label updates for Kisunla and Amyvid, reviewing reusable claims for scientific accuracy, compliance, and audit readiness.
Earlier, I led editorial teams at Allied Analytics LLP and Brentwood Infoscribe Ltd., and mentored editors on quality standards and review practices. At Eli Lilly and Company, I mentored three team members and supported consistent quality through structured review and feedback.

